Search Results - cancer

58 Results

Sort By:

Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors

Abstract: Hypoxia is a characteristic of many solid tumors resulting from accelerated cellular proliferation and inadequate vascularization. HIF-1 is a transcription factor critical for maintaining cellular homeostasis in, and adaptively responding to, low oxygen environments. HIF-1 becomes activated through binding to the transcriptional co-activator...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Kirk Gustafson, Martin Schnermann, Susanna Chan, Paresma Patel, William Figg, James McMahon

Keywords(s): CANCER, Hypoxia Inhibitor, Malaria, small molecule

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Radioprotectants and Tumor Radiosensitizers Targeting Thrombospondin-1 and CD47

Abstract: The National Cancer Institute''s Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize CD47-targeting agents as radioprotectants and tumor sensitizers. Radiation therapy not only damages cancer cells, but it also damages healthy...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): David Roberts, Justin Maxhimer, Jeff Isenberg

Keywords(s): CANCER, CD47, Morpholinos, Radioprotective Agents, Radiotherapeutics, Thrombospondin-1 (TSP1), Tumor Sensitizers

Category(s): Collaboration Sought > Licensing

Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer

Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development, where it is known as physiological angiogenesis, and during the growth of solid tumors, where it is known as pathological angiogenesis. CD276, also known as B7-H3, is a cell surface tumor endothelial...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Steven Seaman, Saurabh Saha, Xaioyan Zhang, Dean Welsch, Gary Decrescenzo

Keywords(s): Antibody Drug Conjugate (ADC), B7-H3, CANCER, CD276, Dimitrov, immuno-oncology, Immunotherapy, Monoclonal Antibody

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies

Abstract: T cells currently employed for T cell-based immunotherapies are often senescent, terminally differentiated cells with poor proliferative and survival capacity. Recently, however, scientists at the National Cancer Institute (NCI) identified and characterized a new human memory T cell population with stem cell-like properties. Since these T...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Luca Gattinoni, Nicholas Restifo, Mario Roederer, Enrico Lugli

Keywords(s): anti-tumor activity, CANCER, Gattinoni, GSK-3beta, Immunotherapy, Infection, Stem Cell, T cell, WNT

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Therapeutics

Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents

Abstract: Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly...

Published: 5/14/2025 | Updated: 8/2/2023 | Inventor(s): Ira Pastan, Masanori Onda, Tapan Bera, Mitchell Ho

Keywords(s): ANTIBODY, CANCER, CAR, chimeric antigen receptor, diagnostic, IMMUNOCONJUGATES, IMMUNOTOXINS, MESOTHELIN, Pastan, therapeutic

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene

Summary: The NCI seeks parties interested in licensing this mouse model, including the mice, organs, tissues, and other derivatives from mice carrying deletions of the Zbtb7b gene. Description: The Zbtb7b gene encodes the zinc finger transcription factor ThPOK (also known as cKrox) that promotes CD4 lineage differentiation in immature T cells. CD4+...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s):

Keywords(s): Autoimmunity, Bosselut, CANCER, CD4, cKrox, Helper T Cell, Infection, LYMPHOCYTE, Memory T Cell, Oncology, ThPOK, transgenic mice, Zbtb7b, Zinc Finger Transcription Factor

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials, TherapeuticArea > Immunology

Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells

Abstract: The tumor-suppressor p53 protein plays a major role in tumor development. Most human cancers fail to normally activate wild-type p53, which is at least partly responsible for the unregulated growth of cancer cells and their failure to undergo apoptosis. While many chemotherapeutics enhance p53 levels, their non-specific DNA damage (genotoxicity)...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Allan Weissman, Yili Yang

Keywords(s): APOPTOSIS, CANCER, HDM2 Inhibitor, p53 Activation, Weissman

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Human and Improved Murine Monoclonal Antibodies Against CD22

Summary: Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22. Description of Technology: CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Dimiter Dimitrov, Xiaodong Xiao, Ira Pastan

Keywords(s): antibodies, ANTIGEN, B-CELL, B-Cell Lymphoma, Bcl, CANCER, CD22, Chronic Lymphoblastic Leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Human, monoclonal, NHL, non-Hodgkins lymphoma, Oncology

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent

Description of Technology: Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Ira Pastan, Xiu Fen Liu, Tapan Bera, Masanori Onda, Mitchell Ho

Keywords(s): ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)

Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment. The...

Published: 4/23/2025 | Updated: 8/2/2023 | Inventor(s): Scott Durum, Julie Hixon, Wenqing Li, Scotch Walsh, Lila Kashi

Keywords(s): Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

1 2 3 4 5 6